How profitable is NRX Pharmaceuticals Inc. (NRXP)?

In FY 2025 (10-K), NRXP converted $1.2M of revenue into a 58.8% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / NRXP / financials

VTVT (24) NTHI (31) ORGO (34) UNCY (31) ⌘ Pro Terminal →

NRX Pharmaceuticals Inc. (NRXP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.17 -4.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.15

NRX Pharmaceuticals Inc. (NRXP) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $94.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NRXP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NRXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, NRX Pharmaceuticals Inc. (NASDAQ: NRXP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $2.17 (-4.40% 1D, market cap $94.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NRXP ranks #927 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NRXP compare to VTVT and NTHI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NRXP carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of 58.8%, and ROIC of -35.0%. By comparison, VTVT (vTv Therapeutics Inc. (Class A)) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $95.5M) and NTHI (NeOnc Technologies Holdings Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $91.4M). Among the 5-stock peer group, NRXP leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NRXP?

▼

Per NRXP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001719406), NRX Pharmaceuticals Inc. generated $1.2M in revenue (-97.6% YoY), -$28.6M in net income, and -$14.1M in free cash flow against $13.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.15 (-0.98%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NRXP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (25/100 Composite)

🔍 WHY NRXP SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 58.8% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.59+1.5% Next Q

Q2 (-2Q)

Grade E$2.63+2.3% Next Q

Q3 (-1Q)

Grade E$2.69-19.3% Next Q

Current

Grade E$2.17-10.7% Hist 90D α

Trajectory: E (33) → E (25)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NRXP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NRXP currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.98) and Max Pain ($2.28) forces dealer call-delta covering toward $5.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NRXP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NRXP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 25%NO 75%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NRXP Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $77.9M

FY24

Rev $51.8M

FY25

Rev $1.2M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.2M	58.8%	-80%	-$28.6M	-$14.1M	-45%
FY 2024	$51.8M	58.8%	-35.7%	-$25.1M	-$10.6M	-45%
FY 2023	$77.9M	58.8%	-35.7%	-$30.1M	-$21.7M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NRXP)

✓Walkthrough of NRXP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NRXP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -28.62%🛡️ HOLDING TREND SUPPORT

2026-11-04O $2.27H $2.27L $2.17C $2.17VOL 2.51M

RES: $2.77SUP: $2.08SMA50: $2.98SMA200: $2.97

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NRXP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NRXP Butterfly Map → + Track NRXP →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -97.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NRXP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NRXP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NRXP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRXP)

Health Care Rank #927 of 1015 ⚔️ VTVT vs NRXP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NRXP vs. VTVT, NTHI, ORGO, UNCY)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NRX Pharmaceuticals Inc. (NRXP) ranks #927 by composite RQD confidence (25/100, grade E) and #660 by equity capitalization ($94.0M). Within this direct 5-issuer industry benchmark cohort, NRXP leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. ORGO currently holds the highest overall quantitative score in the immediate peer group at 34/100 (E) compared with NRXP at 25/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NRXP ACTIVE NRX Pharmaceuticals Inc.	E	25/100	—	58.8%	-35.0%	-4.40%	$94.0M	Benchmark Subject
VTVT vTv Therapeutics Inc. (Class A)	E	24/100	—	—	-35.0%	-4.05%	$95.5M	/vtvt-vs-nrxp →
NTHI NeOnc Technologies Holdings Inc.	E	31/100	—	—	-35.0%	-5.83%	$91.4M	/nthi-vs-nrxp →
ORGO Organogenesis Holdings Inc. (Class A)	E	34/100	—	—	17.1%	-1.64%	$97.2M	/orgo-vs-nrxp →
UNCY Unicycive Therapeutics Inc.	E	31/100	—	—	-35.0%	-6.68%	$97.2M	/uncy-vs-nrxp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001719406 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NRX Pharmaceuticals Inc. (NRXP) reported GAAP revenue of $1.2M (-97.6% vs. FY2024 revenue of $51.8M , and -98.4% cumulative change since FY2023) , GAAP net income of -$28.6M, operating cash flow of -$14.1M, and free cash flow of -$14.1M (-32.7% YoY). On the balance sheet, NRXP closed FY2025 with $13.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.2M	-$28.6M	-$14.1M	-$14.1M	$13.0M	—
FY2024 (FY)	2024-12-31	$51.8M	-$25.1M	-$10.6M	-$10.6M	$3.7M	—
FY2023 (FY)	2023-12-31	$77.9M	-$30.1M	-$21.7M	-$21.7M	—	—

3. NRXP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NRXP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NRXP compare to VTVT and NTHI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NRXP?

Where is NRXP trading relative to its 50-day, 200-day, and 52-week technical levels?

NRXP last traded at $2.17 (-4.40% on volume of 2,510,371 shares), positioning the stock -27.18% below its 50-day simple moving average ($2.98) and -26.94% below its 200-day simple moving average ($2.97). Across its 52-week range of $1.62 to $5.05, NRXP sits at the 16.0% percentile with a 14-day RSI of 30.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.90 to $2.44).

Direct Sub-Reports: NRXP RQD Cockpit NRXP 12M Forecast NRXP Earnings & Move NRXP Dividends & DRIP NRXP Insiders & 13F NRXP Whale Options NRXP Profit Sankey NRXP News & Why

ROARABLE RATING BRIEF • RQD 25/100 (E) ✓ SEC XBRL & RQD VERIFIED

NRXP — NRX Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

NRX Pharmaceuticals Inc. (NRXP) earns a live Roarable RQD composite score of 25/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.17 (-4.40% 1D, market capitalization $94.0M).

Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 58.8%, operating margin of -60.0%, and free cash flow yield of -12.25%.
Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (4/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

NRX Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NRX Pharmaceuticals Inc. (NRXP) reported $1.2M in annual revenue (up from $51.8M in FY2024, -97.6% YoY) and -$28.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($77.9M revenue, -$30.1M net income) through FY2025, NRXP scaled operating cash flow to -$14.1M and free cash flow to -$14.1M, backed by $13.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 25/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -12.25% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $1.62 – $5.05 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector context available is the Health Care classification and the beta of 1.0, which suggests the stock moves in line with the broader market rather than with a distinct sector factor.

Key Question #1: Can NRXP sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.2M and free cash flow of -$14.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is NRXP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NRXP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NRX Pharmaceuticals Inc. (NRXP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NRXP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

NRx Pharmaceuticals, Inc. (NRXP) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering NRX Pharmaceuticals Inc. (NRXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 1d ago

NRx Pharmaceuticals (NRXP) Stock Jumps Over 26% After Hours: What's Behind the Surge?

TradingView report covering NRX Pharmaceuticals Inc. (NRXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

NRx Pharmaceuticals, Inc. (NRXPW) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering NRX Pharmaceuticals Inc. (NRXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 2d ago

Tests found preservative-free ketamine stayed pure, potent and sterile for two years.

Stock Titan report covering NRX Pharmaceuticals Inc. (NRXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 2d ago

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga report covering NRX Pharmaceuticals Inc. (NRXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 2d ago

NRx Pharmaceuticals Sets 2026 Virtual Annual Meeting Date

The Globe and Mail report covering NRX Pharmaceuticals Inc. (NRXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 2d ago

Why is NRX Pharmaceuticals stock surging today?

Investing.com report covering NRX Pharmaceuticals Inc. (NRXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stocktwits • 2d ago

FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions

Stocktwits report covering NRX Pharmaceuticals Inc. (NRXP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NRXP Bull vs. Bear Conversation Board — What's Your Call at $2.17?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NRXP 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $2.72 (+19.8%)

📌 Pinned Debate

Cash rose to $7.8M in FY 2025 and the stock posted a 26% after-hours jump per the TradingView headline, signaling a potential near-term

Long NRXP at $2.27 targeting $2.72. Cash rose to $7.8M in FY 2025 and the stock posted a 26% after-hours jump per the TradingView headline, signaling a potential near-term catalyst.. Institutional whale score is 4/20 and the risk/reward vs. the $1.62 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@TapeReader_Pro Agree on the RQD 25/100 quality, though with 1.0 beta I'm scaling in with half-size at $2.27 and keeping dry powder in case we test $2.11.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $1.91 (-15.9%)

Spot @ $2.27

FY 2025 FCF of -$14.1M against $7.8M cash, with ROIC at -35% and an insider conviction pillar of only 3/20, points to cash burn and lim

Here is the bear case nobody on the bull side wants to address on NRXP: FY 2025 FCF of -$14.1M against $7.8M cash, with ROIC at -35% and an insider conviction pillar of only 3/20, points to cash burn and limited insider confidence.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.